OLIG2 and glioblastoma: IHC analysis revealed decreased staining for SUV39H1, Ki67, and OLIG2 in SUV39H1-KD tumors compared with the controls (P < 0.001; Figure 8, E and F), demonstrating that targeting SUV39H1 can disrupt GSC proliferation and stemness, thereby inhibiting GBM growth in vivo.